GLOBAL BLOOD THERAPEUTICS Stock News

The blood-disorder specialist sells itself in a deal with an enterprise value of around $5.4 billion.

Upgrades For iRobot Corp (NASDAQ:IRBT), JP Morgan upgraded the previous rating of Underweight to Neutral. In the second quarter, iRobot showed an EPS of $0.35, compared to $0.27 from the year-ago qua

The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.

Source: ra2 studio/Shutterstock Last week, Global Blood Therapeutics (NASDAQ: GBT ) stock was thrust into the spotlight on reports of a potential buyout bid from Pfizer (NYSE: PFE ). Today, though, Pf

Gartman said he likes stocks in motion as the long-time Wall Street veteran says it's still a bear market for equities.

Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion

U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session. Carvana Co. (NYSE: CVNA) jumped 40.1% to clo

Pfizer inked a $5.4 billion deal Monday to buy Global Blood Therapeutics, confirming rumors that sent GBT stock skyrocketing last week. The post Pfizer Inks $5.4 Billion Deal To Acquire Global Blood T

Pfizer said it would pay $68.50 per share for Global Blood Therapeutics which sells a sickle cell disease treatment called Oxbryta

Pfizer Inc. (PFE) announced it is buying Global Blood Therapeutics (GBT) for $5.4 billion. This is why.

The New York drugmaker is buying Global Blood Therapeutics, which sells a drug for sickle-cell disease and has two in development. It will pay $68.50 per share.

Gainers Cooper-Standard Holdings Inc. (NYSE: CPS) jumped 69.6% to close at $8.53 on Friday following better-than-expected Q2 results. Intelligent Living Application Group Inc. (NASDAQ: ILAG) surged 6

Pfizer Inc. PFE, -1.18% has agreed to buy Global Blood Therapeutics Inc. [s :gbt] in a deal valued at $5.4 billion, the companies said Monday, confirming a report by the Wall Street Journal. Pfizer wi

Pfizer Inc said on Monday it has agreed to buy blood disorder drugmaker Global Blood Therapeutics in a $5.4 billion deal, as it looks to fortify its product pipeline.

Pfizer Inc. PFE, -1.18% has reached an agreement to buy Global Blood Therapeutics Inc. [s :gbt] in a deal valued at $5.4 billion, the Wall Street Journal reported, citing people familiar with the matt